CytomX Therapeutics, Inc. (NASDAQ:CTMX) is one of the best stocks under $5 with highest upside potential. On October 28, ...

Intensity Therapeutics ( INTS ), with a ~$13M market cap, closed up nearly 395% Thursday after publishing phase 1/2 results ...

Mycenax Biotech Inc. (TWO:4726), a leading biologics CDMO based in Taiwan, announced the signing of a License Agreement with Japan-based RIN Institute Inc., granting Mycenax rights to apply RIN's prop ...

In recognition of Pancreatic Cancer Awareness Month, join us to explore how cutting-edge technologies are transforming our ...

Glioblastoma (GBM), the most aggressive primary brain tumor, continues to portend a poor prognosis with median survival under ...

Oncotelic Therapeutics, Inc. (OTCQB: OTLC), a biopharmaceutical company founded to discover, create, test, and deliver transformative medicines to treat cancer patients by leveraging its novel PDAOAI ...

Researchers at The University of Texas MD Anderson Cancer Center, in collaboration with BostonGene, conducted the largest and ...

An under-appreciated cancer mutation has been found to block immune checkpoint inhibitor drugs, offering a new approach to ...

The poster will be available on November 7, 2025 under the “Our Approach—Presentations & Publications” section of the Xilio Therapeutics website at www.xiliotx.com.

Scientists have developed a way to engineer immune cells that specifically target tumors. The application of engineering ...

The paper features a comprehensive evaluation of data, including disease control rate, overall survival, immune activation, ...

A research team of Lee Je-joong and Jung Sung-hoon and Dr. Lee Min-geun of the Department of Hematology at Hwasun Chonnam ...